Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.
Athersys was founded in 1995 and is headquartered in Cleveland, US
Key People at Athersys
Gil Van Bokkelen
Chairman & CEO
William Lehmann Jr
Executive Vice President and Chief Scientific Officer
Executive Vice President, Regenerative Medicine
Vice President, Global Regulatory Affairs
Closing share price
Athersys's current market capitalization is $129 M.
Athersys's revenue is $11.9 M in FY, 2015 which is 636.17% increase from the previous period.
Operating cash flow
Athersys Market Value History
We estimate that Athersys's current employees are approximately 18% female and 82% male.
Market Position – Health, clinics, product development, pharma